<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="app1table4" position="float"><label>Appendix 1&#8212;table 4.</label><caption><title>Test for a linear relationship between drug-related effects on model-parameters and DA baseline.</title></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">R&#178;</th><th colspan="2">&#223;<sub>1</sub> estimate</th><th colspan="2">&#223;<sub>1</sub><italic>p</italic>-value</th></tr><tr><th/><th>sEBR</th><th>WMC</th><th>sEBR</th><th>WMC</th><th>sEBR</th><th>WMC</th></tr></thead><tbody><tr><td><inline-formula><mml:math id="inf166"><mml:mi>&#946;</mml:mi></mml:math></inline-formula> (P-D)</td><td>2.13e<sup>&#8722;5</sup></td><td>1.52e<sup>&#8722;3</sup></td><td>4.75e<sup>&#8722;05</sup></td><td>2.25e<sup>&#8722;03</sup></td><td>.98</td><td>.84</td></tr><tr><td><inline-formula><mml:math id="inf167"><mml:mi>&#966;</mml:mi></mml:math></inline-formula> (P-D)</td><td>1.87e<sup>&#8722;2</sup></td><td>4.25e<sup>&#8722;2</sup></td><td>1.40e<sup>&#8722;02</sup></td><td>&#8722;1.19e<sup>&#8722;01</sup></td><td>.46</td><td>.27</td></tr><tr><td><inline-formula><mml:math id="inf168"><mml:mi>&#961;</mml:mi></mml:math></inline-formula> (P-D)</td><td>5.91e-<sup>3</sup></td><td>2.42e-<sup>3</sup></td><td>&#8722;4.89e<sup>&#8722;03</sup></td><td>&#8722;1.76e<sup>&#8722;01</sup></td><td>.68</td><td>.79</td></tr><tr><td><inline-formula><mml:math id="inf169"><mml:mi>&#946;</mml:mi></mml:math></inline-formula> (P-H)</td><td>2.47e<sup>&#8722;2</sup></td><td>2.93e<sup>&#8722;2</sup></td><td>1.64e<sup>&#8722;03</sup></td><td>1.01e<sup>&#8722;02</sup></td><td>.40</td><td>.36</td></tr><tr><td><inline-formula><mml:math id="inf170"><mml:mi>&#966;</mml:mi></mml:math></inline-formula> (P-H)</td><td>9.58e<sup>&#8722;3</sup></td><td>3.36e<sup>&#8722;2</sup></td><td>&#8722;1.01e<sup>&#8722;02</sup></td><td>&#8722;1.06e<sup>&#8722;01</sup></td><td>.60</td><td>.32</td></tr><tr><td><inline-formula><mml:math id="inf171"><mml:mi>&#961;</mml:mi></mml:math></inline-formula> (P-H)</td><td>4.61e<sup>&#8722;2</sup></td><td>1.18e<sup>&#8722;2</sup></td><td>&#8722;9.01e<sup>&#8722;03</sup></td><td>&#8722;2.57e<sup>&#8722;01</sup></td><td>.25</td><td>.56</td></tr><tr><td><inline-formula><mml:math id="inf172"><mml:mi>&#946;</mml:mi></mml:math></inline-formula> (D-H)</td><td>1.57e<sup>&#8722;3</sup></td><td>7.83e<sup>&#8722;3</sup></td><td>1.57e<sup>&#8722;03</sup></td><td>7.83e<sup>&#8722;03</sup></td><td>.43</td><td>.49</td></tr><tr><td><inline-formula><mml:math id="inf173"><mml:mi>&#966;</mml:mi></mml:math></inline-formula> (D-H)</td><td>1.02e<sup>&#8722;3</sup></td><td>2.95e<sup>&#8722;4</sup></td><td>&#8722;3.93e<sup>&#8722;03</sup></td><td>1.20e<sup>&#8722;02</sup></td><td>.86</td><td>.93</td></tr><tr><td><inline-formula><mml:math id="inf174"><mml:mi>&#961;</mml:mi></mml:math></inline-formula> (D-H)</td><td>4.11e-<sup>3</sup></td><td>5.69e-<sup>4</sup></td><td>&#8722;4.07e<sup>&#8722;02</sup></td><td>&#8722;8.54e<sup>&#8722;02</sup></td><td>.73</td><td>.90</td></tr></tbody></table><table-wrap-foot><fn><p>Note. Drug-related differences (P: placebo, D: L-dopa, H: haloperidol) of model parameters for all participants (n&#160;=&#160;31). Baseline dopamine (DA) function was assessed by the two behavioral DA proxies spontaneous eye blink rate (sEBR) and working memory capacity (WMC). For the latter, the first principal component across three different WMC tasks was used, denoted by WMCPCA. The column &#8216;R&#178;&#8217; denotes the R&#178;-values of the linear regressions. The columns &#8216;&#946;1 estimate&#8217; and &#8216;&#946;1 p-value&#8217; show for each linear model the estimated value and p-value of the &#946;1 regression coefficient, respectively. &#946;: softmax parameter; &#966;: exploration bonus parameter; &#961;: perseveration bonus parameter</p></fn></table-wrap-foot></table-wrap>